Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
No new studies have been requested
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
BVX-0922 to target colorectal cancer under investigator-sponsored IND
It is an application to automate statistical analysis and reporting for clinical research.
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Subscribe To Our Newsletter & Stay Updated
